SUMMARY Sequential doses of 5 mg of oral prazosin hydrochloride were administered to eight patients with severe chronic congestive heart failure refractory to conventional therapy. Initial doses of the drug produced marked increases in cardiac index (+0.87 I/min/m2) associated with substantial decreases in left ventricular filling pressure (-10.7 mm Hg), total systemic vascular resistance (2118 to 1154 dyn-sec-cm-5), and heart rate (89 to 76 beats/min). However, serial administration of the same dose at 12-24-hour intervals was accompanied by the rapid development of tachyphylaxis, such that the magnitude of hemodynamic effects with second doses was less than 50% of the magnitude of effects seen with first doses (p < 0.01), and third doses produced no overall significant hemodynamic responses. Diuresis with furosemide failed to restore the circulatory effects of prazosin, and the use of 10-mg doses improved cardiovascular performance to only a small extent. Only two of eight patients had sustained hemodynamic responses large enough to justify chronic oral ambulatory therapy. Administration of oral hydralazine caused hemodynamic improvement superior to even high-dose prazosin therapy (p < 0.02).
THE BENEFICIAL HEMODYNAMIC and clinical effects of peripheral vasodilators in patients with
severe heart failure are well established,' 5 but the search continues for a well-tolerated oral agent which is chronically effective for the therapeutic reduction of preload and afterload. Although nitrates are orally active, their duration of action is short, and they have minimal effects on cardiac output.6' 7 The use of hydralazine results in marked increases in cardiac output (CO), significant reductions in left ventricular filling pressure (LVFP),4 and amelioration of clinical symptoms,3 but is often accompanied by poorly tolerated adverse effects.8' 9 Therefore, the recent demonstration of balanced preload and afterload reduction with prazosin'0' 1' has stimulated interest in its use in chronic ambulatory therapy.
Prazosin exerts a peripheral vasodilator action by producing a-sympathetic blockade;21-6 some have proposed an additional direct smooth muscle relaxant effect mediated by increased intracellular levels of cyclic AMP due to drug-induced phosphodiesterase inhibition. '7 Despite extensive experience in antihypertensive therapy, previous work with prazosin in heart failure has involved hemodynamic monitoring of only initial doses of the drug;10 as a result, the ability of maintenance therapy to produce sustained reduction of preload and afterload has not been demonstrated. As tolerance to the effects of other afterload-reducing agents has been demonstrated in the therapy of hypertension9 18, 19 and has also been suspected with prazosin,20 an examination of the hemodynamic effects of repeated doses of prazosin in patients with severe heart failure seems warranted.
Methods

Patient Population
We evaluated eight patients with severe chronic congestive heart failure refractory to optimal therapy with digitalis and diuretics. All patients had persistent dyspnea at rest or on minimal exertion and developed fatigue and azotemia with progressive increments in diuretic dosage. Clinical information concerning these patients is summarized in table 1. There were seven men and one woman, with a mean age of 64 years (range 56-71 years). The etiology of heart failure was idiopathic cardiomyopathy in five and ischemic cardiomyopathy in three. Diagnosis was confirmed by cardiac catheterization in four patients, all of whom had angiographic ejection fractions less than 35%. All had clinical or angiographic evidence of mitral regurgitation. The duration of heart failure ranged from 7 months to 8 years. All patients were in normal sinus rhythm, and all were receiving therapeutic doses of digoxin and furosemide, the latter in daily doses of 80-800 mg. Two patients were also taking spironolactone. Six patients had been treated with sublingual or oral isosorbide dinitrate without clinical benefit. One patient had responded hemodynamically and clinically to hydralazine therapy, but had discontinued its use due to adverse effects (rash and hemolysis). One patient had previously taken prazosin, but not for the preceding three months.
All patients were studied during a period of relative clinical stability. Bed rest was maintained, and patients were fed 2-gram sodium diets. Nitrates, an- Abbreviations: NYHA class = New York Heart Association functional class; MR = mitral regurgitation; NSR = normal sinus rhythm; CM = idiopathic cardiomyopathy; ICM = ischemic cardiomyopathy (cardiomyopathy with clinical history of infarction and electrocardiographic and/or angiographic evidence of segmental scar).
tiarrhythmics, hydralazine, and potassium-sparing diuretics were discontinued for at least 5 days before study.
Hemodynamic Measurements
After we obtained written, informed consent from all patients, we performed right heart catheterization using a triple lumen flow-directed balloon-tipped catheter (Kimray Medical Associates, Oklahoma City) through which measurements of right atrial, pulmonary arterial, and pulmonary capillary wedge pressures were made. Arterial cannulae (Angiocath, Deseret Pharmaceuticals) were inserted percutaneously or by cutdown into the radial or brachial artery in all patients. Measurements were made using Bentley Trantec #800 pressure transducers with zero reference level at the midaxillary line with the patient supine; all pressures were recorded in this position on a Hewlett Packard multichannel modular display (Hewlett Packard, Inc, Sanborn Division, Waltham, Massachusetts). LVFP was measured as pulmonary capillary wedge pressure or as pulmonary arterial diastolic pressure after its identity with wedge pressure was established. CO was determined by thermodilution using the same catheter connected to a bedside CO computer (Columbus Instruments, Columbus, Ohio) using room temperature injectate (23-25°C) as 10-ml boluses of 5% dextrose in water; injection was made reproducibly with the assistance of a manually triggered injector (Columbus Instruments), and the determinations were performed in triplicate. Heart rates (HR) were determined from a continuously recorded ECG.
Administration of Drugs
We designed a protocol to compare first doses of prazosin with subsequent doses administered at 12-24-hour intervals under identical control hemodynamic conditions. After digoxin and furosemide had been withheld for 24 hours, baseline determinations of the following hemodynamic variables were made for at least 3 hours to ensure stability of the control hemodynamic state: mean systemic arterial pressure (MAP), heart rate, left ventricular filling pressure, mean pulmonary artery pressure (MPAP), mean right atrial pressure (MRAP) and cardiac output. Each patient then received 5 mg of prazosin hydrochloride (as Minipress capsules, Pfizer Laboratories) administered orally; the mean dose normalized for body weight was 86 ,g/kg (range 47-106 mg/kg). We chose a dose of 5 mg because of its equivalence to 100 mg of hydralazine in the treatment of hypertension;2' this dose of hydralazine had previously been very effective in the therapy of heart failure. 4 22 Second, third, and fourth doses of prazosin were then administered at 12-24-hour intervals under similar hemodynamic monitoring as follows. A second dose of 5 mg of prazosin was administered when the hemodynamic variables returned to control values after the first dose of the drug. After its peak effects were observed, digoxin (0.125-0.25 mg) and furosemide (100-200 mg) were administered intravenously (4-6 hours after the second dose); in this way, digoxin and furosemide therapy was maintained but spaced at intervals that permitted independent evaluation of the effects of prazosin. Only one dose of daily maintenance digoxin and furosemide therapy was omitted during the trial. A third dose of 5 mg of prazosin was given 12-18 hours after administration of digoxin and furosemide. If the third dose produced minimal hemodynamic effects, a 10-mg dose of prazosin was administered 12 hours later; if this dose produced significant hemodynamic responses, patients received a second 10-mg dose of the drug. If prazosin had no persistent effects, a 100-mg dose of hydralazine hydrochloride (Apresoline tablets, Ciba Pharmaceutical Company) was given and its hemodynamic effects were observed before we discontinued invasive monitoring. Special care was taken to ensure similarity of all control hemodynamic states before (MPAP -LVFP)/CO (dyn-sec-cm-5) Statistical analysis was performed using the t test for paired data. The hemodynamic responses to first doses of prazosin at peak effect (1-2.5 hours after administration) were compared with the peak effects of second, third, and fourth doses of the drug administered under similar control hemodynamic states.
Results
Hemodynamic changes with sequential doses of prazosin are summarized in tables 2, 3A, 3B, 3C, and 3D, and figures 1-4.
First Dose Prazosin
Administration of the initial 5-mg dose of prazosin produced a marked improvement in cardiac performance. In the eight patients studied, the CI increased from 1.68 to 2.55 I/min/M2 (+0.87 + 0.08) and right and left ventricular filling pressures dropped substantially (12.4 to 4.9 mm Hg, -7.5 ± 0.8 and 25.3 to 14.6 mm Hg, -10.7 ± 0.8, respectively). There was a marked drop in MAP (83.0 to 64.1 mm Hg, -18.9 ± 2.7) and MPAP (40.1 to 28.4 mm Hg, -11.7 ± 1.5). TSVR was reduced 45% (2118 to 1154 dyn-sec-cm-5) and PVR declined 41% (461 to 271 dynsec-cm-5). HR slowed from 89 to 76 beats/min (-13 ± 1). All changes were significant (p < 0.001).
The onset of action of first doses of prazosin was observed at 30-90 minutes. Peak CO occurred at 60-120 minutes, but maximal decreases in LVFP and MAP were usually delayed until 90-150 minutes after 533 (table 2) , and six patients manifested no discernible effects. Administration of 10-mg doses in five of these six patients produced significant hemodynamic effects in only three (tables 3A-3D); with second 10-mg doses of prazosin in two patients, the same attenuation of effect was observed. Overall, the hemodynamic changes with first 10-mg doses were significantly different from control, but were small. All six patients continued on prazosin therapy for 3-42 days (mean 16 ± 6 days), with progressive increments in dosage up to 45 comparable to those used in our study. This negative chronotropic effect is attenuated after repeated doses of prazosin and disappears with maintenance therapy. In contrast to our experience, Awan et al.23 reported sustained clinical improvement with the use of maintenance prazosin therapy in doses of 8-28 mg daily in nine patients with severe heart failure due to ischemic heart disease. However, they evaluated the improvement of ventricular function only by echocardiography and exercise testing. Unfortunately, echocardiography is of limited value in the evaluation of left ventricular function in ischemic heart disease.26 Moreover, one must cautiously interpret improvements in exercise tolerance by exercise testing, since significant improvement has been observed with placebo therapy,27 emphasizing the need for a doubleblind interpretation of data. More importantly, invasive studies were performed for only first doses of prazosin and for only 6 hours, and thus the reported clinical improvement in dyspnea and fatigue after 2-4 months of therapy has no invasive hemodynamic substantiation. In contrast, using invasive monitoring, we found only two patients in whom prazosin had sustained hemodynamic effects after 3-4 days of therapy. In most of our patients we observed only minimal hemodynamic and clinical effects, even with high doses of prazosin (10 mg per dose) administered as maintenance therapy.
An exaggerated response to first doses of prazosin with subsequent marked attenuation of effect after repeated doses is well-known in the treatment of hypertension.2834 Manifested as a syndrome of marked postural hypotension, this "first dose phenomenon" was initially considered to be an idiosyncratic reaction33 or due to poor renal clearance. 33 Further experience has shown that the effect could be precipitated in all patients, especially if first doses were larger than 1 mg or if the patients were 537 physically stresscd30 38 or sodium-depleted. 16 The severe postural hypotension was maximal at 1-2 hours and persisted for 8-10 hours. 28 30, 36 These effects disappeared despite continued therapy, and a repeat challenge with the same dose 2 days later had little demonstrable effect.32' 36 Our invasively derived data establish a hemodynamic counterpart to this first dose phenomenon in the therapy of heart failure.
The mechanism of rapid tachyphylaxis to prazosin is unknown. Induction of hepatic enzymes with enhanced metabolic degradation of the drug has been proposed,30 but plasma levels of prazosin are much higher after 2 days of therapy than with initial doses.28' 36 Others have suggested that an expansion of plasma volume may be responsible for the tolerance,20 but diuresis with high doses of furosemide failed to restore hemodynamic responsiveness in our patients. A more plausible mechanism for tachyphylaxis may be the rapid development of tolerance to any chronically established a-sympathetic blockade. 29 33 Although early work supported the idea of a direct smooth muscle vasodilator effect mediated by phosphodiesterase inhibition,28 more recent studies have indicated that all drug action may be completely explained by sympathetic blockade, 13' 14, 16, 37, 38 specifically of the postsynaptic a-sympathetic receptor,'5 since pretreatment with a-sympathetic blockers can totally abolish the effects of prazosin.13 1 As rapid tolerance to drug-induced a-sympathetic blockade is well-known,'8' 39 the marked attenuation of prazosin's effect after first doses probably represents a similar phenomenon. Further work is needed to determine how long it takes to recover responsiveness to prazosin and other a-blockers so that subsequent doses of the drug can produce hemodynamic effects similar to first doses.
The effectiveness of prazosin maintenance therapy in antihypertensive treatment programs is controversial. Initial, enthusiastic reports have mostly been from uncontrolled studies34' 40 or from studies of prazosin in combination with other agents. 2' 3, 41-43 Some controlled studies have indicated that prazosin has little overall hypotensive action, while others have suggested that chronic ambulatory use does result in sustained antihypertensive effects, although the decrease in blood pressure is relatively small,43'4 rather large doses are required,45 and only a minority of patients manifest a sustained therapeutic effect. '6' Additional work is necessary to determine if doses of prazosin even higher than those we have used will result in a higher percentage of patients who manifest a sustained response to prazosin in the therapy of either hypertension or heart failure. However, the lack of any additional effect with higher doses has been suggested in animal14' 16 and clinical studies. 44' 46, 48, 49 Furthermore, the safety of chronic, large doses of prazosin must be tested.
We believe that hydralazine remains the most consistently effective agent for acute and chronic therapeutic afterload reduction in congestive heart failure. Sustained clinical improvement does occur,3 50 and hemodynamic monitoring for 6 weeks and longer has revealed no evidence of tachyphylaxis.50 '1 The five patients in our study who were treated with hydralazine after exhibiting total tolerance to prazosin had overall hemodynamic responses similar to those reported by us and others4 ' 22, 52 and superior even to those induced by high doses of prazosin. The major limitation of hydralazine therapy in our experience remains a high frequency of adverse effects (intractable headaches9 and precipitation of ischemic events)8 which unfortunately restricts its therapeutic use in a significant number of patients.
Our study underscores the need for sustained invasive hemodynamic monitoring to confirm the improvement in left ventricular performance during administration of vasodilator agents before we make conclusions about therapeutic effectiveness or a commitment to chronic therapy. We found that the use of oral prazosin for combined preload and afterload reduction in the therapy of patients with severe congestive heart failure is associated with the rapid development of tachyphylaxis and loss of clinical effectiveness after several days of therapy, despite impressive initial responses to the drug. This tolerance precludes the use of prazosin for chronic ambulatory vasodilator therapy except in the few patients who manifest sustained beneficial hemodynamic effects.
